Kinarus AG
Ticker: KNRS Exchange: SIX
Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus’s unique and innovative combinatorial therapeutic candidate has broad potential to transform numerous therapeutic areas.

First transaction on KIN001

Kinarus have announced the signing of an agreement with ChaoDain (Hangzhou) Investment Management (CDIM) for a CHF 1.5m convertible loan that will form the basis for the development of KIN001 in the treatment of idiopathic pulmonary fibrosis (IPF) in China. This is an important validation of the potential of KIN001 in IPF and could be the first of a sequence of transactions that result in development collaborations on KIN001, and not just in IPF.

We regard the investment by ChaoDain Investment Management, and the raising of the profile of KIN001 in IPF, as a significant positive step in validating KIN001 in its proposed inflammatory indications as well as providing a welcome cash inflow.

However we shall not be changing our valuation or forecasts until at least the release of Kinarus’ full-year 2022 results at the end of this month.


Download as a PDF file
26810392321 - kinarus-ag
Return to Kinarus AG

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates